- Home
- REGN vs PWR Comparison
REGN vs PWR Comparison
Compare REGN & PWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- PWR
- Stock Information
- Founded
- REGN 1988
- PWR 1997
- Country
- REGN United States
- PWR United States
- Employees
- REGN N/A
- PWR N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- PWR Engineering & Construction
- Sector
- REGN Health Care
- PWR Industrials
- Exchange
- REGN Nasdaq
- PWR Nasdaq
- Market Cap
- REGN 59.5B
- PWR 65.1B
- IPO Year
- REGN 1991
- PWR 1998
- Fundamental
- Price
- REGN $654.37
- PWR $444.89
- Analyst Decision
- REGN Buy
- PWR Buy
- Analyst Count
- REGN 21
- PWR 21
- Target Price
- REGN $779.00
- PWR $419.89
- AVG Volume (30 Days)
- REGN 1.0M
- PWR 1.1M
- Earning Date
- REGN 10-28-2025
- PWR 10-30-2025
- Dividend Yield
- REGN 0.55%
- PWR 0.09%
- EPS Growth
- REGN 2.88
- PWR 24.72
- EPS
- REGN 41.59
- PWR 6.75
- Revenue
- REGN $14,247,800,000.00
- PWR $27,191,171,000.00
- Revenue This Year
- REGN $1.34
- PWR $18.79
- Revenue Next Year
- REGN $5.23
- PWR $12.46
- P/E Ratio
- REGN $15.49
- PWR $67.21
- Revenue Growth
- REGN 2.89
- PWR 18.72
- 52 Week Low
- REGN $476.49
- PWR $227.08
- 52 Week High
- REGN $844.51
- PWR $469.43
- Technical
- Relative Strength Index (RSI)
- REGN 67.60
- PWR 55.86
- Support Level
- REGN $625.14
- PWR $433.66
- Resistance Level
- REGN $664.00
- PWR $459.13
- Average True Range (ATR)
- REGN 17.50
- PWR 15.73
- MACD
- REGN 4.95
- PWR -0.65
- Stochastic Oscillator
- REGN 89.45
- PWR 62.20
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About PWR Quanta Services Inc.
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two segments: electric infrastructure and underground utility and infrastructure.